DelveInsight’s analysts estimate that the alcohol use disorder market is expected to show positive growth, with growing awareness about AUD as a serious health condition and reduced stigma surrounding ...
Adial Pharmaceuticals ( (ADIL) ) has shared an announcement.
Adial Pharmaceuticals (ADIL) announced patent number 12150931 was issued on November 26, 2024 by the United States Patent and Trademark Office, ...
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial” or the "Company”), a clinical-stage biopharmaceutical company focused on ...
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced that patent number 12150931 was issued by the United States Patent and ...
Adial Pharmaceuticals, Inc. (ADIL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...
Adial Pharmaceuticals, Inc. (ADIL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...
Revenue for the quarter came in at $0.00 versus the... ByInvesting.com • Mar 30, 2023 Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of ...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback